Aeschylus

Aeschylus

While the insulin pump market may not be a war in the true sense recent developments have proved that the Greek warrior Aeschylus was correct when he said, “In war, truth is the first casualty.” Let’s start right here in my backyard at Tandem.

Since February 22, 2024, the day after Tandem released full year and fourth quarter results for 2023 shares are up over 40%. Keep in mind earnings were lackluster at best and the outlook going forward wasn’t all that impressive either. We speculated that the move upward was being driven by rumors that Roche was . . .

This content is restricted to subscribers. Please subscribe.

Already have an account? Please login.